Humacyte, Inc.
HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designedā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.33
Price+1.53%
$0.02
1Y
Price
Market Cap
$210.761m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-9876.1%
EBITDA Margin-12511.0%
Net Profit Margin-8963.8%
Free Cash Flow MarginRevenue
$8.046m
-
1y CAGR-33.3%
3y CAGR-19.0%
5y CAGREarnings
-$58.661m
+60.5%
1y CAGR-266.5%
3y CAGR-186.2%
5y CAGREPS
-$0.45
+64.3%
1y CAGR-248.4%
3y CAGR-165.8%
5y CAGRBook Value
$4.052m
$138.795m
Assets$134.743m
Liabilities$15.123m
DebtDebt to Assets
10.9%
-0.4x
Debt to EBITDAFree Cash Flow
-$106.291m
-6.6%
1y CAGR-14.4%
3y CAGR-8.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company